Sage Therapeutics restructures, laying off 33% workforce for Zurzuvae launch and drug pipeline focus.
Sage Therapeutics is undergoing a major restructuring, laying off over 165 employees, about 33% of its workforce, to focus on the launch of its postpartum depression drug, Zurzuvae. The company aims to improve its financial stability and prioritize its drug development pipeline following setbacks in clinical trials. The changes are expected to complete by the end of 2024 and will help position Sage for long-term growth.
October 17, 2024
5 Articles